Acute lymphoblastic leukemia.
暂无分享,去创建一个
A. Zelenetz | M. Millenson | O. Frankfurt | K. Gregory | K. Ballen | D. DeAngelo | S. O'brien | H. Carraway | S. Terezakis | M. Boyer | A. Rao | S. Coutre | P. Brown | S. Goorha | J. Alvarnas | P. Aoun | Naresh Bellam | W. Blum | P. Coccia | J. Cultrera | L. Damon | D. Douer | H. Frangoul | S. Petersdorf | G. Uy | M. Wetzler | Maoko Naganuma | M. Naganuma
[1] H. Sather,et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. , 2012, The Lancet. Oncology.
[2] Maria Grazia Valsecchi,et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Kantarjian,et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.
[4] M. Schrappe,et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.
[6] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[7] Z. Estrov,et al. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] M Feychting,et al. A pooled analysis of magnetic fields and childhood leukaemia , 2000, British Journal of Cancer.
[9] A. Cherry,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.
[10] Ya-Zhen Qin,et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia , 2012, Journal of Hematology & Oncology.
[11] D. Boggs. Hematopoietic Stem Cell Theory in Relation to Possible Lymphoblastic Conversion of Chronic Myeloid Leukemia , 2005 .
[12] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.
[13] J. Rowley. Chromosomes in leukemia and lymphoma. , 1978, Seminars in hematology.
[14] C. Pui. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia , 2015, Frontiers of Medicine.
[15] A. Taylor,et al. Leukemia and lymphoma in ataxia telangiectasia. , 1996, Blood.
[16] H. Kantarjian,et al. Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.
[17] Y. Ikeda,et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.
[18] Kevin K Dobbin,et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.
[19] C. Pui,et al. A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL) , 2011 .
[20] S. Bertolone,et al. Acute psychosis complicating induction therapy for acute lymphoblastic leukemia. , 1983, The Journal of pediatrics.
[21] R. Foà,et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.
[22] M. Tormo,et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group , 2010, Haematologica.
[23] J. Hernández-Rivas,et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. , 2005, Haematologica.
[24] J. Aster,et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Lilleyman,et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.
[26] F. Behm,et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.
[27] M. Andreeff,et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Tei,et al. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions , 2008, International journal of hematology.
[29] Elaine Coustan-Smith,et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.
[30] S. Kornblau,et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia , 1997, Leukemia.
[31] D. Campana,et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.
[32] T. Lipp,et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.
[33] Elaine Coustan-Smith,et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.
[34] C. Stiller,et al. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. , 1994, British Journal of Cancer.
[35] James Allan,et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk , 2010, Nature Genetics.
[36] W. Benedict,et al. Correlation between prognosis and bone marrow chromosomal patterns in children with acute nonlymphocytic leukemia: similarities and differences compared to adults. , 1979, Blood.
[37] M. Loh,et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse , 2013, Nature Genetics.
[38] M. Béné,et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. , 2004, Blood.
[39] N. Heerema,et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] C. Pui,et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.
[41] C. Bloomfield,et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia , 2013, Cancer.
[42] M. Loh,et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] T. Lebien,et al. Origin of chronic myelocytic leukemia in a precursor of pre-B lymphocytes. , 1979, The New England journal of medicine.
[44] W. Stock. Adolescents and young adults with acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[45] Takashi Akasaka,et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.
[46] J. Bourhis,et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.
[47] B. Summersgill,et al. PHILADELPHIA-POSITIVE BLAST CRISIS MASQUERADING AS ACUTE LYMPHOBLASTIC LEUKÆMIA IN CHILDREN , 1976, The Lancet.
[48] M. Konopleva,et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience , 2014, Leukemia.
[49] R. Arceci,et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] J. Esteve,et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.
[51] J. Downing,et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.
[52] J. Chessells. Acute lymphoblastic leukemia. , 1982, Seminars in hematology.
[53] J. Lilleyman,et al. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] T. Kalina,et al. Acute lymphoblastic leukemia incidence during socioeconomic transition: selective increase in children from 1 to 4 years , 2002, Leukemia.
[55] J. Whang‐Peng,et al. Cytogenetic studies in acute lymphocytic leukemia: special emphasis in long-term survival. , 1976, Medical and pediatric oncology.
[56] M. Relling,et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients , 2003, Leukemia.
[57] M. Relling,et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. , 2010, Blood.
[58] Gamal Abdul Hamid,et al. Classification of acute leukemia. , 2011, Annals of internal medicine.
[59] H. Brenner,et al. Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States , 2014, PloS one.
[60] H. Gschaidmeier,et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphobla , 2003, Annals of Hematology.
[61] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] J. Tchinda,et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome , 2014, Leukemia.
[63] J. Neglia,et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. , 2002, Blood.
[64] E. Thiel,et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. , 1984, Blood.
[65] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[66] M. Konopleva,et al. Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) , 2014, Cancer.
[67] H. Dombret,et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[68] S. Mustjoki,et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.
[69] J. Whitlock. Down syndrome and acute lymphoblastic leukaemia , 2006, British journal of haematology.
[70] C. Pui,et al. The eighth international childhood acute lymphoblastic leukemia workshop (‘Ponte di Legno meeting’) report: Vienna, Austria, April 27–28, 2005 , 2006, Leukemia.
[71] Rocco Piazza,et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.
[73] S. Sallan,et al. Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. , 1978, Blood.
[74] P. Neiman,et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. , 1979, The New England journal of medicine.
[75] C. Bloomfield,et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. , 2008, Blood.
[76] F. Behm,et al. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII , 1997, Leukemia.
[77] A. Ferrando,et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). , 2009, Blood.
[78] J. Beyene,et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis , 2011, Leukemia.
[79] M. Muckenthaler,et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.
[80] I. Flinn,et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.
[81] P. Dreger,et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia , 2013, Leukemia.
[82] U. Dührsen,et al. Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) , 2007, Cancer.
[83] T. Ito,et al. Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion , 1997, Bone Marrow Transplantation.
[84] G. Gustafsson,et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden , 2006, Cancer.
[85] E. Gehan,et al. Prognostic factors in acute leukemia. , 1976, Seminars in oncology.
[86] W. Woods,et al. The occurrence of leukemia in patients with the Shwachman syndrome. , 1981, The Journal of pediatrics.
[87] A. Pession,et al. Clofarabine, cyclophosphamide and etoposide as single‐course re‐induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia , 2009, British journal of haematology.
[88] A. Angiolillo,et al. A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report , 2009, Pediatric blood & cancer.
[89] P. Carbone,et al. THE DISTRIBUTION OF THE PHILADELPHIA CHROMOSOME IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA. , 1963, Blood.
[90] J. Burchenal,et al. Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.
[91] J. Rowley,et al. Banding studies of chromosomal abnormalities in patients with acute lymphocytic leukemia. , 1979, Cancer research.
[92] E. Thiel,et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. , 2014, Blood.
[93] Simona Soverini,et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.
[94] S. Armstrong,et al. Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] R. Herrmann,et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.
[96] D. Fabbro,et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia , 2004, Nature Genetics.
[97] Christopher B. Miller,et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.
[98] H. Kantarjian,et al. Central nervous system relapse in adults with acute lymphoblastic leukemia , 2002, Cancer.
[99] H. Sather,et al. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] H. Kantarjian,et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.
[101] P. Philip,et al. Philadelphia chromosome in acute lymphocytic leukaemia , 2009 .
[102] Y. Ishigatsubo,et al. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion , 2011, Leukemia & lymphoma.
[103] W. Hofmann,et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[104] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[105] M. Schrappe,et al. ACUTE LYMPHOBLASTIC LEUKEMIA AND KLINEFELTER SYNDROME IN CHILDREN: Two Cases and Review of the Literature , 2004, Pediatric hematology and oncology.
[106] C. Pui. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. , 2006, Hematology. American Society of Hematology. Education Program.
[107] C. Pui,et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] D. Campana,et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR , 2005, British journal of haematology.
[109] H. Kantarjian,et al. Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.
[110] H. Sather,et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] W. Crist,et al. Lymphoblastic conversion in chronic myelogenous leukemia. , 1978, Pediatrics.
[112] A. Bleyer,et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel , 2011, Leukemia & lymphoma.
[113] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[114] M. Baccarani,et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia , 2006, Clinical Cancer Research.
[115] C. Heavey,et al. Terminal transferase expression in the differential diagnosis of acute leukemias. Eastern Cooperative Oncology Group. , 1996, Leukemia & lymphoma.
[116] P. Sonneveld,et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands , 2004, Leukemia.
[117] R. Larson,et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.
[118] G. Harrison,et al. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X , 1997, British journal of haematology.
[119] A. Tsiatis,et al. High‐dose dexamethasone for refractory or relapsing multiple myeloma , 1991, American journal of hematology.
[120] H. Kantarjian,et al. Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL) , 2012 .
[121] R. Larson,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[122] H. Macdonald,et al. Notch signaling in the immune system. , 2010, Immunity.
[123] T. Naoe,et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] T. A. Lister,et al. The effect of food on the oral administration of 6-mercaptopurine , 2004, Cancer Chemotherapy and Pharmacology.
[125] Jinny Park,et al. Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study , 2013 .
[126] B. Löwenberg,et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.
[127] F. Reyes,et al. The Blast Crisis of Chronic Granulocytic Leukaemia: Megakaryoblastic Nature of Cells as Revealed by the Presence of Platelet‐Peroxidase—A Cytochemical Ultrastructural Study , 1978, British journal of haematology.
[128] M. Palmer,et al. SEX AND PROGNOSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKÆMIA , 1978, The Lancet.
[129] R. Williams,et al. Shwachman's syndrome and acute lymphoblastic leukaemia. , 1978, British medical journal.
[130] H. Kantarjian,et al. Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.
[131] R. Weinshilboum,et al. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.
[132] Michael C. Rusch,et al. Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia , 2013 .
[133] H. Dombret,et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia , 2010, Haematologica.
[134] M. Tallman,et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. , 2009, Blood.
[135] D. Baltimore,et al. Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma. , 1978, The American journal of medicine.
[136] H. Gadner,et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.
[137] J. Downing,et al. Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia , 2009, Leukemia.
[138] Michael N Dworzak,et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.
[139] Ryan D. Morin,et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.
[140] O. Eden,et al. Acute lymphoblastic leukemia and Klinefelter's syndrome. , 1992, Pediatric Hematology & Oncology.
[141] Paul W. H. I. Parren,et al. Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1 , 2009, The Journal of Immunology.
[142] A. Delannoy,et al. A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL). , 2004, Blood.
[143] S. Richards,et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. , 2003, Blood.
[144] J. Gerss,et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. , 2011, Blood.
[145] M. Baccarani,et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] K. Bhalla,et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.
[147] Lee G Luna,et al. Manual of histologic staining methods of the Armed forces institute of pathology , 1968 .
[148] E. Thiel,et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. , 2012, Blood.
[149] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[150] H. Kantarjian,et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.
[151] E. Thiel,et al. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. , 2008, Blood.
[152] J. Lipton,et al. Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy , 2004, Leukemia & lymphoma.
[153] R. Collins,et al. Donor leukocyte infusions in acute lymphocytic leukemia , 2000, Bone Marrow Transplantation.
[154] A. Bleyer,et al. Delays in cancer diagnosis in underinsured young adults and older adolescents. , 2007, The oncologist.
[155] M. Schell,et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. , 1987, The New England journal of medicine.
[156] J. Kawedia,et al. Asparaginase in acute lymphoblastic leukemia. , 2014, Clinical lymphoma, myeloma & leukemia.
[157] J. Cayuela,et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study , 2006 .
[158] L. Kinlen. Infections and immune factors in cancer: the role of epidemiology , 2004, Oncogene.
[159] Z. Estrov,et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells , 2005, Cancer.
[160] L. Foroni,et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[161] M. Tallman,et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.
[162] J. Fiet,et al. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[163] J. Craig,et al. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. , 1991, Leukemia.
[164] H. Dombret,et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. , 2007, Leukemia research.
[165] M. Greaves. Infection, immune responses and the aetiology of childhood leukaemia , 2006, Nature Reviews Cancer.
[166] C. Pui,et al. Adult acute lymphoblastic leukemia , 2010, Cancer.
[167] W. Jędrzejczak,et al. Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study , 2008, British journal of haematology.
[168] C. Pui,et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements , 2003, Leukemia.
[169] J. V. van Dongen,et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.
[170] M. Zhou,et al. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. , 1997, Pediatric hematology and oncology.
[171] H. Dombret,et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. , 2009, Blood.
[172] M. Relling,et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[173] J. Nachman. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia , 2005, British journal of haematology.
[174] K. Sakamoto,et al. Topics in pediatric leukemia--acute lymphoblastic leukemia. , 2005, MedGenMed : Medscape general medicine.
[175] R. Larson,et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. , 2007, Blood.
[176] A. Denman,et al. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. , 1978, The Journal of clinical investigation.
[177] C. Mullighan. Genomic characterization of childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.
[178] J. Whelan,et al. Recruitment of adolescents and young adults to cancer clinical trials--international comparisons, barriers, and implications. , 2010, Seminars in oncology.
[179] A. Pistorio,et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients , 2012, Leukemia & lymphoma.
[180] R. Barr,et al. Preliminary evidence for the common origin of a lympho-myeloid complex in man. , 1978, Acta haematologica.
[181] W. Evans,et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.
[182] R. Good,et al. B and T lymphocytes in primary immunodeficiency disease in man. , 1973, The Journal of clinical investigation.
[183] H. Dombret,et al. Clofarabine Combinations in Adults with Refractory/Relapsed Acute Lymphoblastic Leukemia (ALL): A GRAALL Report , 2011 .
[184] M. Devidas,et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. , 2005, Blood.
[185] H. Kantarjian,et al. Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia , 2013 .
[186] R. Pieters,et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.
[187] L. Staudt,et al. Oncogenic mechanisms in Burkitt lymphoma. , 2014, Cold Spring Harbor perspectives in medicine.
[188] P. Fialkow. The origin and development of human tumors studied with cell markers. , 1974, The New England journal of medicine.
[189] M. Greaves,et al. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia , 2004, Oncogene.
[191] E. Papaemmanuil,et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia , 2009, Nature Genetics.
[192] D. J. King,et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia , 1999, British journal of haematology.
[193] L. Damon,et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[194] S. Richards,et al. Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 , 2010, British journal of haematology.
[195] E. Passarge. Bloom's syndrome: the German experience. , 1991, Annales de genetique.
[196] E. Forman,et al. Ph1-positive childhood leukemias: spectrum of lymphoid-myeloid expressions. , 1977, Blood.
[197] J. Szer,et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. , 2010, Blood.
[198] Ching-Hon Pui,et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia , 2009, Nature Genetics.
[199] Scott E. Smith,et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[200] M. Greaves,et al. Membrane marker and cell separation studies in Ph1-positive leukemia. , 1978, Blood.
[201] H. Hasle. Pattern of malignant disorders in individuals with Down's syndrome. , 2001, The Lancet. Oncology.
[202] D. Neuberg,et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia , 2010, Pediatric blood & cancer.
[203] T. Naoe,et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia , 2006, Cancer.
[204] P. Nilsson,et al. Prognostic implications of chromosome analysis in acute non-lymphocytic leukemia , 1977 .
[205] L. Robison,et al. Assessment of the interrelationship of prognostic factors in childhood acute lymphoblastic leukemia: A report from Childrens Cancer Study Group , 1980 .
[206] H. Kantarjian,et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.
[207] G. Garcia-Manero,et al. Activity of alemtuzumab in patients with CD52‐positive acute leukemia , 2006, Cancer.
[208] A. Baruchel,et al. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE) , 2000, British Journal of Cancer.
[209] R. Brynes,et al. Bone marrow aspiration and trephine biopsy. An approach to a thorough study. , 1978, American journal of clinical pathology.
[210] D. Hoelzer,et al. Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[211] D. Campana,et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.
[212] F. Huguet. [Adult acute lymphoblastic leukemia]. , 2011, La Revue du praticien.
[213] J. Baars,et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. , 2009, Blood.
[214] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[215] M. Perales,et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors , 2014, Haematologica.
[216] J. V. van Dongen,et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.
[217] D. Teachey,et al. T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL , 2013 .
[218] C. Sebban,et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. , 2000, Hematology/oncology clinics of North America.
[219] N. Heerema,et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. , 2006, Blood.
[220] J. Kersey,et al. Prognostic significance of surface marker analysis in childhood non‐hodgkin's lymphoproliferative malignancies , 1976, American journal of hematology.
[221] H. Dombret,et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[222] M. Tormo,et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[223] R. Fanin,et al. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. , 2009, Leukemia research.
[224] H. Kantarjian,et al. Clofarabine in leukemia , 2010, Expert review of hematology.
[225] P. H. Fitzgerald,et al. Karyotope and survival in human acute leukemia. , 1976, Journal of the National Cancer Institute.
[226] P. Jacobs,et al. Cytogenetic studies on bone-marrow in chronic myeloid leukaemia. , 1963, Lancet.
[227] J. Román,et al. MYELOPEROXIDASE GENE EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKAEMIA , 1997, British journal of haematology.
[228] D. Scheinberg,et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia , 2002, Cancer.
[229] L. Foroni,et al. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value , 2000, British journal of haematology.
[230] H. Einsele,et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.
[231] L. Vidal,et al. Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis. , 2009 .
[232] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[233] H. Kantarjian,et al. Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) , 2008 .
[234] R. Foà,et al. Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .
[235] T. Brümmendorf,et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. , 2012, Blood.
[236] C. Pui,et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[237] G. Gatta,et al. Adult acute lymphoblastic leukaemia. , 2004, Critical reviews in oncology/hematology.
[238] R. Aguiar,et al. TEL‐AML1 fusion in acute lymphoblastic leukaemia of adults , 1996, British journal of haematology.
[239] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[240] H. Einsele,et al. Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial , 2011 .
[241] P. Kearns,et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia , 2011, British journal of haematology.
[242] H. Kantarjian,et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.
[243] D. Blaise,et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison , 2009, Leukemia.
[244] D. Baltimore,et al. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. , 1978, The New England journal of medicine.
[245] L. J,et al. Rearrangement of the MLL Gene Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia , Regardless of Presenting Age , 2002 .
[246] C. Pui,et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. , 2007, Blood.
[247] S. Richards,et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia , 2004, British journal of haematology.
[248] M. Kizaki,et al. TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression. , 2004, Molecular cancer research : MCR.
[249] E. Thiel,et al. FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors , 2013, PloS one.
[250] D. Campana,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse , 2004, Leukemia.
[251] Michel Sadelain,et al. Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.
[252] C. Bloomfield,et al. The philadelphia chromosome in acute leukemia , 1978, Virchows Archiv. B, Cell pathology.
[253] D. Steensma. Oddballs: acute leukemias of mixed phenotype and ambiguous origin. , 2011, Hematology/oncology clinics of North America.
[254] S. Bohlander,et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. , 2013, Blood.
[255] C. Bloomfield,et al. Lymphocytes bearing receptors for both sheep erythrocytes and complement in patients with neoplastic and non-neoplastic diseases. , 1977, Clinical immunology and immunopathology.
[256] B. Kennedy,et al. Chronic myelogenous leukemia presenting in blastic crisis , 1972, Cancer.
[257] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[258] M. Verneris,et al. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome‐positive acute lymphoblastic leukemia (ALL) , 2009, Pediatric blood & cancer.
[259] D. Grant,et al. Effect of allopurinol on caffeine disposition in man. , 1986, British journal of clinical pharmacology.
[260] Cheng Cheng,et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.
[261] Michel Sadelain,et al. Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.
[262] M. Schrappe,et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[263] Gamal Abdul Hamid. 1 Classification of Acute Leukemia , 2012 .
[264] M. Relling,et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.
[265] H. Kantarjian,et al. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia , 2009, Cancer.
[266] A. Rausen,et al. PHILADELPHIA CHROMOSOME IN ACUTE LYMPHATIC LEUKÆMIA OF CHILDHOOD , 1977, The Lancet.
[267] M. Kneba,et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.
[268] H. Gundacker,et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia , 2010, British journal of haematology.
[269] W. Hiddemann,et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.
[270] R. Pieters,et al. Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art. , 1994, Medical and pediatric oncology.
[271] S. de Vos,et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.
[272] M. Greaves,et al. Leukemia in twins: lessons in natural history. , 2003, Blood.
[273] C. Pui,et al. L‐asparaginase treatment in acute lymphoblastic leukemia , 2011, Cancer.
[274] F. Guilhot,et al. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia , 2009, Pediatric blood & cancer.
[275] T. Barbui,et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.
[276] H. Kantarjian,et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. , 2011, Clinical lymphoma, myeloma & leukemia.
[277] T. Enver,et al. Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia , 2008, Science.
[278] A. Gürgey,et al. Acute lymphoblastic leukemia associated with Klinefelter syndrome. , 1994, Pediatric hematology and oncology.
[279] C. Pui,et al. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. , 2009, Seminars in oncology.
[280] J. McElnay,et al. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. , 2008, British journal of clinical pharmacology.
[281] Susan J. Lindemulder,et al. Successful Intermittent Prophylaxis With Trimethoprim/Sulfamethoxazole 2 Days per Week for Pneumocystis carinii (jiroveci) Pneumonia in Pediatric Oncology Patients , 2007, Pediatrics.
[282] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[283] J. Downing,et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[284] J. Radich,et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. , 2007, Blood.
[285] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[286] M. Baccarani,et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. , 2007, Haematologica.
[287] Takashi Akasaka,et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.
[288] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[289] J. Shuster,et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906 , 2011, Pediatric blood & cancer.
[290] E. Thiel,et al. CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). , 2005, Blood.
[291] Steven M Kornblau,et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.
[292] T. Caspersson,et al. Identification of human chromosomes by DNA-binding fluorescent agents , 2004, Chromosoma.
[293] P. D. Dal Cin,et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[294] K. Yan,et al. Magnetic fields exposure and childhood leukemia risk: a meta-analysis based on 11,699 cases and 13,194 controls. , 2014, Leukemia research.
[295] W. Evans,et al. Disposition of antineoplastic agents in the very young child. , 1992, The British journal of cancer. Supplement.
[296] Ganser,et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. , 1988, Blood.
[297] C. Pui,et al. Thiopurine methyltransferase activity in American white subjects and black subjects , 1994, Clinical pharmacology and therapeutics.
[298] A. Hüttmann,et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. , 2011, Blood.
[299] M. Territo,et al. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia , 1993, American journal of hematology.
[300] R. Pazdur,et al. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. , 2008, The oncologist.
[301] Dario Campana,et al. Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[302] M. Labopin,et al. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 2014, Bone Marrow Transplantation.
[303] B K Tang,et al. Variability in caffeine metabolism , 1983, Clinical pharmacology and therapeutics.
[304] S. Richards,et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial , 2005, British journal of haematology.
[305] M. Tallman,et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. , 2006, Blood.
[306] R. Foà,et al. E2A–PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features , 2003, British journal of haematology.
[307] Cheng Cheng,et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.
[308] M. Loh,et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[309] T. Lister,et al. Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine‐prednisolone in the acute phase of Ph1 positive leukemia , 1979, Cancer.
[310] J. Radich,et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia , 2014, British journal of haematology.
[311] L. Robison,et al. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia , 2014, Cancer.
[312] R. Bassan,et al. Current and future management of Ph/BCR-ABL positive ALL , 2014, Expert review of anticancer therapy.
[313] G. Fabbri,et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia , 2008, Leukemia.
[314] C. Li,et al. ACID PHOSPHATASE ISOENZYME IN HUMAN LEUKOCYTES IN NORMAL AND PATHOLOGIC CONDITIONS , 1970, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[315] J. Cayuela,et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[316] W. Hofmann,et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. , 2003, Blood.
[317] M. Tallman,et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. , 2014, Blood.
[318] A. Levis,et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[319] K. Neville,et al. Successful Treatment of Fanconi Anemia and T-Cell Acute Lymphoblastic Leukemia , 2012, Case reports in hematology.
[320] F. Behm,et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.
[321] H. Kantarjian,et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia , 2010, Cancer.
[322] A. Moorman,et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. , 2010, Blood.
[323] Christian Urban,et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.
[324] L. Kaplow. SIMPLIFIED MYELOPEROXIDASE STAIN USING BENZIDINE DIHYDROCHLORIDE. , 1965, Blood.
[325] M. Andreeff,et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[326] W. Młynarski,et al. The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations , 2009, Clinical and Experimental Medicine.
[327] E. Domany,et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.
[328] Rajesh Chopra,et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.
[329] A. Hagemeijer,et al. Bone Marrow Karyotypes of Children with Nonlymphocytic Leukemia , 1979, Pediatric Research.
[330] J. Kurtzberg,et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[331] J. Radich,et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. , 2007, Blood.
[332] C. Bloomfield,et al. Prognostic significance of the Philadelphia chromosome in acute lymphocytic leukemia , 1980 .
[333] P. Kebriaei,et al. The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia , 2012, Current Hematologic Malignancy Reports.
[334] Hans Clevers,et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.
[335] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[336] J. Cayuela,et al. Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 Study , 2012 .
[337] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[338] T. Naoe,et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. , 2004, Blood.
[339] N. Heerema,et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.
[340] E. Thiel,et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.
[341] T. Naoe,et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. , 2006 .
[342] O. Haas,et al. Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose‐escalating infusion of donor leucocytes , 1997, British journal of haematology.
[343] M. Loh,et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.
[344] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[345] M. Relling,et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[346] Terry L. Smith,et al. Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.
[347] M. Loh,et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). , 2007, Blood.
[348] F. Balis,et al. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. , 1986, Pediatric hematology and oncology.
[349] D. Collier,et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. , 1999, Pharmacogenetics.
[350] M. Slovak,et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. , 2008, Blood.
[351] D. Le Paslier,et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. , 1995, Blood.
[352] W. Hofmann,et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations , 2012, Blood Cancer Journal.
[353] J. Tjio,et al. Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration. , 1962, Stain technology.
[354] J. Sierra,et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. , 2008, Blood.
[355] C. Bloomfield,et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. , 2005, Blood.
[356] G. Koren,et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. , 1990, The Journal of pediatrics.
[357] M. Maris,et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia , 2011, Haematologica.
[358] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[359] Ulrich Göbel,et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[360] J. Ford,et al. Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) , 2004, Leukemia & lymphoma.
[361] Edward J. Lee,et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. , 1998, Blood.
[362] E. Bruera,et al. Difficulties in diagnosing neuropsychiatric complications of corticosteroids in advanced cancer patients: two case reports. , 2000, Journal of pain and symptom management.
[363] S. Lawler,et al. Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. , 1978, British medical journal.
[364] M. Greaves,et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[365] C. Bloomfield,et al. Cytochemical profiles in acute lymphoblastic leukemia , 1979 .
[366] H. Kantarjian,et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α , 2004 .
[367] Huanhuan Sun,et al. Survival improvement by decade of patients aged 0–14 years with acute lymphoblastic leukemia: a SEER analysis , 2014, Scientific Reports.
[368] G. Janossy,et al. The Ph1 Chromosome in Childhood Leukaemia , 1979, British journal of haematology.
[369] Kiran C. Bobba,et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.
[370] H. Dombret,et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study , 2006, Leukemia.
[371] A. Vora. Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia , 2011, British journal of haematology.
[372] K. Akashi,et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study) , 2013, Journal of Hematology & Oncology.
[373] Martin C. Müller,et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. , 2009, Blood.
[374] G. Lenz,et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .
[375] J. Lilleyman,et al. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. , 1996, Therapeutic drug monitoring.
[376] M. Baccarani,et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. , 2002, Blood.
[377] W. Hop,et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[378] M. Tuncer,et al. Acute lymphoblastic leukemia in fanconi's anemia , 1994, American journal of hematology.
[379] S. Richards,et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials , 2007, Pediatric blood & cancer.
[380] D. Hoelzer,et al. Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.
[381] M. Greaves,et al. Blast Crisis of Chronic Myeloid Leukaemia (CML): I. PRESENTATION SIMULATING ACUTE LYMPHOID LEUKAEMIA (ALL) , 1976, British journal of haematology.
[382] S. Rives,et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome‐positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL‐94, ALL‐99 and ALL‐2005 , 2011, British journal of haematology.
[383] J. Downing,et al. Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.
[384] M. Loh,et al. Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group , 2010 .
[385] W. Zuelzer,et al. Long‐term cytogenetic studies in acute leukemia of children; The nature of relapse , 1976, American journal of hematology.
[386] J. L. Goodman,et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.
[387] K. Yamada,et al. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2002, Bone Marrow Transplantation.
[388] H. Dombret,et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.
[389] R. Larson,et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study , 2010, American journal of hematology.
[390] B. Asselin,et al. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. , 1999, Advances in experimental medicine and biology.
[391] L. Silverman,et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2010, Blood.
[392] H. Cavé,et al. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .
[393] C. Pui,et al. A 50-year journey to cure childhood acute lymphoblastic leukemia. , 2013, Seminars in hematology.
[394] J. Cayuela,et al. First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia , 2008 .
[395] B. Cho,et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[396] K. Kreuzer,et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.
[397] E. Thiel,et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. , 1995, Annals of internal medicine.
[398] Robert Huether,et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.
[399] S. Armstrong,et al. Targeting epigenetic programs in MLL-rearranged leukemias. , 2011, Hematology. American Society of Hematology. Education Program.
[400] J. Oldenburg,et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2007, Blood.
[401] M. Patnaik,et al. Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia , 2013, Blood Cancer Journal.
[402] W. Crosby,et al. Cytochemical identification of monocytes and granulocytes. , 1971, American journal of clinical pathology.